Further Strengthening America’s Supply Chain and National Security Act

This bill requires drug manufacturers to annually report the sources and percentages of key ingredients used in their products. It directly affects companies holding FDA-approved drug applications by mandating transparency about where critical ingredients (both active and inactive) are sourced. The bill also adds new inspection criteria for drug facilities, focusing on reliance on foreign adversaries and dependency on single global suppliers for essential medicines. Additionally, it updates rules to prioritize U.S. or allied-made pharmaceutical ingredients for government procurement, aiming to reduce supply chain vulnerabilities. All reported ingredient data will be shared with the Department of Defense and published publicly in aggregate form, without revealing proprietary details.